23andMe Investor Presentation Deck

'610 Phase 2a Data: Estimated Timeline* 1400 mg Q1 CCRCC OV NE Q2 SCLC 2023 TMB-H/MSI-H Q3 Q4 -600 mg Q1^ Q2 Safety: N= ~55-60 pts Efficacy: N= ~25-30 pts OV NE First Efficacy Assess. First Efficacy Assess. ^Genotyping, tumor (archival) CD200/R1 IHC, tumor RNAseq, and pre/on-treatment tumor immunophenotyping exploratory analyses to identify potential correlates with activity 2024 First Efficacy Assess. Q3 Q4 Safety: N= ~90 pts Efficacy: N= ≤ ~60 pts 6-mo PFS/OS 6-mo PFS/OS First Efficacy Assess. First Efficacy Assess. N=15 in each cohort Enrolling Fully Enrolled 6-mo PFS/OS 12-mo PFS/OS 12-mo PFS/OS 6-mo PFS/OS 6-mo PFS/OS *Part of the Phase 1/2a clinical study of '610. Strictly estimated dates for discussion purposes only. Based on calendar year. Subject to change. Q1 Q2 Safety: N= ≤ ~100 pts Efficacy: N= ≤ ~75 pts 12-mo PFS/OS 12-mo PFS/OS 12-mo PFS/OS First Efficacy Assess. First Efficacy Assess = ie., Preliminary ORR, patients continue to be scanned First Efficacy Assess. 6-mo PFS/OS 6-mo PFS/OS 2025 Safety in Phase 2a Population Efficacy in Phase 2a Population Q3 Q4 Safety: N= ≤ ~110 pts Efficacy: N= ≤ ~90 pts CCRCC = clear cell renal cell carcinoma OV = ovarian cancer (predominantly non-clear cell histology) SCLC = small cell lung cancer (extensive stage) NE neuroendocrine Copyright © 2024 23andMe, Inc. 12-mo PFS/OS 12-m PFS/OS TMB-H/MSI-H = tumor mutational burden / microsatellite instability high tumors 2026 Q1 23and Me 27

View entire presentation